
|Videos|January 31, 2019
CRC Safety Lead-in: ASCO GI 2019 Updates
Advertisement
Scott Kopetz, MD, PhD, FACP; Ryan Corcoran, MD, PhD; review the design and updated safety lead-in data from the BEACON study looking at the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen also tested in the ANCHOR trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































